Slingshot members are tracking this event:
Axsome's (AXSM) AXS-05 Data Results from GEMINI Phase 3 Trial in Major Depressive Disorder
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Statistically significant improvement versus placebo on all secondary endpoints at week 6, including remission (p<0.001), disease severity (p=0.002), functional impairment (p=0.002), and quality of life (p=0.011)
Slingshot Insights Explained
Dec 16, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Gemini, Ax-05, Phase 3 Study, Major Depressive Disorder